Sotera Health Company (SHC) Q4 Earnings Report Preview
Healthcare services company Sotera Health (NASDAQ:SHC) is set to report its fourth-quarter earnings this Tuesday before the market opens. Here's what investors need to know.
Last quarter, Sotera Health Company surpassed analysts' revenue expectations, reporting revenues of $311.3 million, reflecting a 9.1% year-on-year increase. The company delivered an exceptional performance, beating both the full-year EPS guidance estimates and the analysts' EPS estimates.
What to Anticipate
For this quarter, analysts forecast a revenue growth of 3.3% year-on-year, marking a turnaround from the 6.5% decline observed in the same quarter last year. Over the last month, analysts covering the company have reaffirmed their estimates, indicating confidence in the business as it approaches the earnings report. Historically, Sotera Health has a record of exceeding Wall Street’s expectations.
Insights from peers in the research tools & consumables segment, such as Bio-Techne and Revvity, have provided some context for what Sotera Health may report. Bio-Techne reported flat year-on-year revenue, surpassing expectations by 2%, while Revvity's revenues increased by 5.8%, beating estimates by 1.1%. Following their results, Bio-Techne's shares climbed 1.9%, whereas Revvity's fell by 7%.
Concerns regarding the economy's health alongside the potential for tariffs and corporate tax alterations have created uncertainty throughout 2025. Although some stocks in the research tools & consumables sector have performed well, the group has generally lagged, with average share prices down 3.4% over the past month. Sotera Health's stock has seen a decline of 5.9% in the same timeframe, entering earnings with an average analyst price target of $20.44, compared to its current price of $17.49.
For today's younger investors who may not be familiar with the classic insights found in the Gorilla Game: Picking Winners In High Technology, the principles from that era can still apply. As companies leveraging generative AI continue to emerge, they may very well become the new 'Gorillas' of the market. In this spirit, we are thrilled to present a special free report on a rapidly growing enterprise software stock poised to capitalize on the automation trend while also gearing up for generative AI advancements.
For more insights on Sotera Health and its performance, visit Inside Ticker.